Press Releases
To stay up to date with our development, sign up for a subscription.
2022
2022-07-21 07:00
Second quarter 2022 January-June 2022 CEO comments With a strong balance sheet, we are continuing on our mission towards standard of care During the second quarter, we initiated our clinical program in the US and launched our pharmaceutical Sedaconda...
2022-07-07 08:30
According to the financial calendar, Sedana Medical plans to publish the report for the second quarter 2022 on Thursday July 21 at approximately 07.00 CET. Sedana Medical hereby invites to a presentation of the report on the same day, where the CEO Johannes...
2022-05-11 12:00
Adoption of the profit and loss statement and the balance sheet, the consolidated profit and loss statement and the consolidated balance sheet as well as resolution regarding allocation of profits and discharge from liability The general meeting adopted...
2022-04-28 07:00
First quarter 2022 CEO comments First patient enrolled in US clinical program, sales impacted by significant decline in ventilated patients During the first quarter of 2022, we have continued to make progress on both of our main priorities: we have launched...
2022-04-28 06:50
The studies will compare the safety and efficacy of sedation with inhaled isoflurane delivered via Sedaconda ACD or intravenous propofol in adult mechanically ventilated ICU patients. “Our clinical trials INSPiRE-ICU 1 and 2 are strategically significant...
2022-04-19 08:30
According to the financial calendar, Sedana Medical plans to publish the report for the first quarter 2022 on Thursday April 28 at approximately 07.00 CET. Sedana Medical hereby invites to a presentation of the report on the same day, where the CEO Johannes...
2022-04-07 16:10
In addition to significant events and financial information of 2021, the Annual Report focuses on the strategic priorities and ambitions to introduce inhaled sedation to intensive care. “In 2021, we delivered the highest turnover in our history...
2022-04-07 15:00
In addition to significant events and financial information of 2021, the Annual Report focuses on the strategic priorities and ambitions to introduce inhaled sedation to intensive care. “In 2021, we delivered the highest turnover in our history...
2022-04-07 10:45
Participation A shareholder who wishes to exercise its voting right at the general meeting shall: (A) be entered as a shareholder in the share register kept by Euroclear Sweden AB as of the record date Tuesday, 3 May 2022; and (B) have given notice of...
2022-03-22 08:30
The poster “ICU-free and ventilator-free days with Isoflurane or Propofol as a primary sedative – a post hoc analysis of the Sedaconda study” concludes that isoflurane sedation as the primary sedative during mechanical ventilation in...